Published in Medical Letter on the CDC and FDA, February 26th, 2006
Xanthus recently initiated a multicenter phase 2 study in patients with secondary acute myeloid leukemia (AML) based on data from a phase 1 study, which showed encouraging activity and an acceptable safety profile. Secondary AML refers to those patients who have developed AML based on an antecedent condition, either myelodysplastic syndrome or prior regimens of chemotherapy or...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA